NCT00248404View on ClinicalTrials.gov

NB1011 Administered by Continuous Infusion in Cancers That Overexpress Thymidylate Synthase (TS)

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

155

Participants

Timeline

Start Date

September 30, 2005

Primary Completion Date

December 12, 2007

Study Completion Date

December 12, 2007

Conditions
Tumors
Interventions
DRUG

NB1011

Trial Locations (3)

30033

USC Norris Comprehensive Cancer Center, Los Angeles

55455

University of Minnesota, Minneapolis

M5G 2M9

Princess Margaret Hospital, Toronto

Sponsors

Lead Sponsor

Kiadis Pharma
All Listed Sponsors
lead

Kiadis Pharma

INDUSTRY

NCT00248404 - NB1011 Administered by Continuous Infusion in Cancers That Overexpress Thymidylate Synthase (TS) | Biotech Hunter | Biotech Hunter